Written by: Katie Carter, PharmD, BCPS, Indiana University Health
Olaparib (Lynparza) is a poly ADP-ribose polymerase (PARP) enzyme inhibitor and is currently FDA approved as targeted therapy for BRCA-mutated breast cancer and ovarian cancer. This PQI will highlight its place in therapy in these disease states, safety profiles, and clinical pearls regarding dose adjustment.
Continue reading Olaparib in BRCA-mutated Breast, Ovarian and Pancreatic Cancer
Written by: Martina Fraga, PharmD
This purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate.
Continue reading Ovarian Cancer: PARP Inhibitor Eligibility
Written by: Michelle Phillips, PharmD, University of Rochester Medical Center
The purpose of this PQI is to highlight key criteria for appropriate monitoring, dosing, and administration to improve the dispensing and management of patients taking niraparib (Zejula).
Continue reading Niraparib: dose modifications based on weight and platelet counts